ChemGenex to Present at Canaccord Adams' 27th Global Growth Conference

  
    
  
  
    
      ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced 
      today that it will deliver a presentation at the 27th Annual Canaccord 
      Adams Global Growth Conference in Boston, Massachusetts. Greg Collier, 
      Ph.D., Chief Executive Officer and Managing Director of ChemGenex, is 
      scheduled to present to leading institutional investment representatives 
      at 10am on Thursday, August 9, 2007, at the InterContinental Boston.
    
    
      “We look forward to showcasing ChemGenex to 
      international investors at this year’s Growth 
      Conference,” said Dr. Collier. “This 
      is an ideal venue at which to provide an update of our 
      registration-directed clinical program in chronic myeloid leukemia (CML) 
      patients with the T315I BCR-ABL point mutation and other corporate 
      activities.”
    
    
      An audio webcast of the presentation will be available from the 
      company's website, www.chemgenex.com 
      one hour after the completion of the presentation, and will be available 
      for 90 days after the conference.
    
    
      The Canaccord Adams Global Growth Conference is one of the oldest and 
      largest programs showcasing both publicly traded and privately held 
      growth companies. Many of the presenting public companies are covered by 
      Canaccord Adams’ global team of equity 
      analysts.
    
    
      About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
    
    
      ChemGenex Pharmaceuticals is a pharmaceutical development company 
      dedicated to improving the lives of patients by developing therapeutics 
      in the areas of oncology, diabetes and obesity. ChemGenex harnesses the 
      power of genomics for target discovery and validation, and in clinical 
      trials to develop more individualized therapeutic outcomes. ChemGenex’s 
      lead compound, Ceflatonin®, 
      is currently in phase 2/3 clinical trials for chronic myeloid leukemia 
      (CML) and Quinamed® 
      is in phase 2 clinical development for prostate, breast and ovarian 
      cancers. The company has a significant portfolio of anti-cancer, 
      diabetes and obesity programs, several of which have been partnered with 
      international pharmaceutical companies. ChemGenex currently trades on 
      the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under 
      the symbol "CXSP".
    
    
      Safe Harbor Statement
    
    
      Certain statements made herein that use the words “estimate”, 
      “project”, “intend”, 
      “expect”, “believe” 
      and similar expressions are intended to identify forward-looking 
      statements within the meaning of the US Private Securities Litigation 
      Reform Act of 1995. These forward-looking statements involve known and 
      unknown risks and uncertainties which could cause the actual results, 
      performance or achievements of the company to be materially different 
      from those which may be expressed or implied by such statements, 
      including, among others, risks or uncertainties associated with the 
      development of the company’s technology, the 
      ability to successfully market products in the clinical pipeline, the 
      ability to advance promising therapeutics through clinical trials, the 
      ability to establish our fully integrated technologies, the ability to 
      enter into additional collaborations and strategic alliances and expand 
      current collaborations and obtain milestone payments, the suitability of 
      internally discovered genes for drug development, the ability of the 
      company to meet its financial requirements, the ability of the company 
      to protect its proprietary technology, potential limitations on the 
      company’s technology, the market for the 
      company’s products, government regulation in 
      Australia and the United States, changes in tax and other laws, changes 
      in competition and the loss of key personnel. These statements are based 
      on our management’s current expectations and 
      are subject to a number of uncertainties that could change the results 
      described in the forward-looking statements. Investors should be aware 
      that there are no assurances that results will not differ from those 
      projected.